Long-Term Thesis

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Long-Term Thesis

Mirae compounds only if three independent variables break the right way over the next five-to-ten years — the Korean non-US, non-Chinese back-end supplier position survives the next BIS export-control cycle, customer concentration broadens beyond YILINING PRECISION into either an HBM-adjacent SK Hynix line or a second China memory account, and the new ownership runs a full down-cycle without another rights offering or convertible bond. None of those three is on a credible track today. The historical record — five-year cumulative net income of $0.5M against cumulative free cash flow of −$37M, share count up roughly 169% before a 16:1 reverse split, a 49% ASP cut to land the FY2025 volume surge, a 72/100 forensic risk score, and no disclosed HBM handler product — argues the equity is a cycle-leveraged trade dressed in a 42-year heritage brand, not a long-duration compounder. The 1.0× book floor is genuine and the order cadence into Q1 FY2026 is real, but the durable case rests on customer diversification and cash conversion that have not yet printed. Read this page as the underwriting check on whether Mirae is a multi-year asset or a multi-quarter rental.

The 5-to-10-Year Underwriting Map

The table below names every variable that has to clear for a 5-10 year compounding case to be real. Each row is testable in DART filings, KRX disclosures, or industry data — none requires earnings-call colour or management commentary.

The driver that matters most is customer diversification. Every other variable in the table assumes a baseline of revenue stability that only a second large customer can deliver. The Korean regulatory window is binary and outside management's control. Cash conversion is downstream of customer mix because YILINING's payment cadence dominates the receivables build. Reinvestment economics are downstream of revenue durability. The HBM product gap is real but addressable on a 3-5 year horizon. If Mirae cannot widen the customer book — by either landing a second China memory account or growing SK Hynix into a $10M+ line — the long-term case has no spine. The other six rows are second-order conditions on that one.

Compounding Path

A long-duration case requires plausible math on how reported revenue turns into per-share owner value. The honest answer for Mirae is that the math only works in the upper-bound scenario, and the upper bound requires the customer-diversification milestone above.

The headline chart is not a compounding chart. Revenue moved $41M → $44M → $17M → $18M → $35M in five years — that is amplitude, not growth. Net income summed to $0.5M across the same window. Free cash flow summed to -$37M. ROIC averaged near zero. Share count tripled before a 16:1 reverse split reset the optics. Whatever happens in the next five years, it has to break that pattern decisively, not just print one more strong year.

The compounding math says even in the bull case Mirae is a 1.5-2.0× book outcome on a five-to-ten-year view, not a 5-10× multi-bagger. The difference between the base case ($80-107M equity) and the bull case ($147-194M) is mostly customer diversification, not heroic operating leverage. The bear case ($27-40M) is what FY2023 looked like in a single year — and the same setup is structurally repeatable because the customer concentration has not changed. A reader who buys the long-duration thesis is paying for a 50-100% upside scenario with a 50-60% downside scenario; the asymmetry depends entirely on which variable in the underwriting map prints first.

Durability and Moat Tests

A 5-10 year thesis only survives stress that the business has not faced yet. The four tests below are observable, the signals are specific, and at least one is competitive and one is financial.

Three of the five tests have a refutation signal that has already shown signs of arriving — Changchuan's share has grown from sub-5% to ~12% over five years, the FY2025 OCF print was already negative against record NI, and the HBM product gap was unchanged in the FY2025 AR. The two tests that are still genuinely open are regulatory (binary, outside management's control) and governance (where the January 2026 Nextern injection is the one piece of validating evidence). A long-term reader should weight the regulatory test highest — it is the single variable that can take revenue back to FY2023 levels in one quarter, and no operating improvement can offset that shock.

Management and Capital Allocation Over a Cycle

The post-2023 Nextern-installed management cohort has been in place for under three years, which is too short a sample to underwrite capital-allocation discipline through a full down-cycle. The track record on what they directly control is mixed-to-good: contracts shipped, capital raises closed, side ventures cleanly disclosed and walked back. The track record on what defines a long-term steward — preserving per-share value through a cycle without dilution — is structurally negative because the cohort's only completed cycle so far was the FY2024 capacity build funded by rights offering and CB conversions.

The capital structure history is the most important single fact for the 5-10 year case. Pre-split shares went from 1.66M (FY2021) to 58.2M (FY2024), then 16:1 reverse-split to 4.48M in July 2025. The Nextern stake of 32.31% was assembled largely through CB conversions and bonus issues rather than market purchase. The 2026-01-04 Nextern injection of $4.4M into Mirae is the first clear signal that the controlling chain is willing to fund the operating subsidiary rather than extract from it — but the chain itself (Nextern Roll Korea -$9.0M, SSC -$7.3M FY2025 net losses) has structural cash needs that have not gone away. A 5-10 year underwriter must price the probability that the next downturn is again funded by dilution, because the only completed precedent in the data window is that one.

Three patterns from the History tab are load-bearing. First, management is unusually candid about admitting side-venture failures in print — DeFi, AI healthcare, mining, EV parts all added and then deleted with the same boilerplate "no synergy" footnote. This is the strongest signal in favor of process honesty. Second, the same management has never voluntarily restored per-share economics after dilution — the reverse split reset the optics, not the economic value. Third, no buyback, no dividend, and no meaningful direct insider ownership exists; alignment runs through the Nextern/SSC chain, not Mirae shares. The compounding-friendly version of this management — one that owns equity, allocates capital opportunistically rather than reactively, and treats the cycle as the asset rather than the liability — has not yet been observed.

Failure Modes

Five thesis-killers, each specific enough to be observable in DART or KRX disclosure within a defined window.

Two of the six failure modes are severe and binary (YILINING substitution, BIS expansion); three are high and observable on a 1-3 year cadence; one is medium and follows the industry cycle. A 5-10 year underwriter should weight the binary risks highest because they are uncorrelated with management quality — no operating improvement and no governance reform offsets a single Entity List notice or one Chinese customer's decision to switch suppliers. The fact that three high-severity failure modes (cash conversion, restatement, capital extraction) have not yet definitively printed in 2026 is the only reason the long-term thesis is not already dead.

What To Watch Over Years, Not Just Quarters

Five observable milestones that would update the 5-to-10-year thesis. Each is a disclosure that the company or a regulator must publish; none requires management commentary.

The long-term thesis changes most if the top-customer revenue share falls below 40% with a second named customer above 10% by FY2028 — that single disclosure would simultaneously validate the cash-conversion case (because diversification implies sustainable receivables collection), the regulatory durability case (because YILINING substitution risk shrinks), and the reinvestment case (because plant economics work at multiple customer endpoints). Until that happens, every other improvement in Mirae's reported financials is a single-cycle artifact of one Chinese customer's capex schedule, not a 5-to-10-year compounding story.